Beyond The Algorithm: Why Data Governance Is Key To Pharma's AI Future

The pharmaceutical industry is poised for an AI-driven transformation, with AI-powered drug discovery projected to become a $9.1 billion market by 2030. AI is expected to accelerate clinical trials, optimize supply chains, and personalize patient treatments. Despite the potential, many AI projects fail due to a lack of AI-ready data, which requires quality, structure, context, and timeliness. Robust data governance is essential to bridge this gap, ensuring reliable AI, ethical practices, and patient privacy. Key strategies include building a robust data ecosystem, automating data pipelines, upskilling the workforce, incorporating compliance by design, and optimizing clinical trial supply management.

To fully harness AI's potential, pharmaceutical companies must prioritize data governance and invest in AI-ready data. This involves implementing policies and standards to manage data assets effectively and ethically. By doing so, the industry can improve patient-centricity in trials and bring therapies to market more quickly and safely. The future of pharma is data-driven, and governance is crucial to unlocking AI's full potential, enabling rapid advancements that were once unimaginable.

Key takeaways

AI is transforming the pharmaceutical industry by accelerating drug discovery, optimizing supply chains, and personalizing patient treatments.
Despite the potential of AI, 85% of AI projects fail due to issues like data quality, technical maturity, and skills shortages.
Robust data governance is essential for creating AI-ready data, which includes quality, structure, context, and timeliness.
Key strategies for successful AI implementation include building a robust data ecosystem, automating data pipelines, upskilling the workforce, and ensuring compliance by design.

Beyond The Algorithm: Why Data Governance Is Key To Pharma's AI Future

Key takeaways

Discussion (0)